Search research articles
Contact Us
Filters
Showing results (21-30 of 56) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
Richard M Goldberg, Isabelle Tabah-Fisch, Harry Bleiberg, et al.
Investigational New Drugs
|
May 9, 2008
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer
Daniel G Stover, A Craig Lockhart, Jordan D Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma
Daniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
Lia Gore, Mace L Rothenberg, Cindy L O'Bryant, et al.
Cancer Medicine
|
January 24, 2013
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin, Yang Feng, Jordan Berlin, et al.
Investigational New Drugs
|
October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
Andrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Investigational New Drugs
|
September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
Laura W Goff, Al B Benson, Patricia M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study
Kenneth R Hande, Anne Hagey, Jordan Berlin, et al.
Clinical Colorectal Cancer
|
November 22, 2011
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 56) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
Richard M Goldberg, Isabelle Tabah-Fisch, Harry Bleiberg, et al.
Investigational New Drugs
|
May 9, 2008
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer
Daniel G Stover, A Craig Lockhart, Jordan D Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma
Daniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
Lia Gore, Mace L Rothenberg, Cindy L O'Bryant, et al.
Cancer Medicine
|
January 24, 2013
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin, Yang Feng, Jordan Berlin, et al.
Investigational New Drugs
|
October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
Andrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Investigational New Drugs
|
September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
Laura W Goff, Al B Benson, Patricia M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2006
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study
Kenneth R Hande, Anne Hagey, Jordan Berlin, et al.
Clinical Colorectal Cancer
|
November 22, 2011
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
Kenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.
Page
of 6